Aug 11, 2021 / 03:00PM GMT
Kyle William Rose - Canaccord Genuity Corp., Research Division - Senior Analyst
Good morning, and welcome to the 41st annual Canaccord Genuity Global Growth Conference. My name is Kyle Rose. I'm one of the medical device analyst here at Canaccord Genuity. And I'm very excited to be joined this morning by Insulet, who is a leader in the insulin delivery market and has what we view as one of the best technologies in the space in a very differentiated pay-as-you-go business model.
I'm pleased to be joined today by Bret Christensen, the Chief Commercial Officer; as well as Deb Gordon, who leads IR. So we've got a fireside chat, and we will have an opportunity for Q&A. (Operator Instructions).
Before we begin, I do need to start everyone of these by pointing everybody to any relevant disclosures. If and where they're applicable, you can find them on our conference and/or our firm website.
So there's a lot going on right now that I think makes the diabetes space a really interesting area for investors. And particularly, with Insulet, specifically, you've got compelling tailwinds
Insulet Corp at Canaccord Genuity Growth Conference (Virtual) Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers